Discover how Cabaletta Bio’s innovative T‑cell therapies target B‑cell autoimmune diseases, boosting investor confidence and shaping future treatments.

Cabaletta Bio, Inc. is a biotech company pioneering T cell therapies for autoimmune diseases, with its Rese-cel treatment for Myositis expected to submit for BLA approval in 2027.

Cabaletta Bio’s stock has experienced significant price fluctuations ahead of its anticipated 2027 BLA submission for Rese-cel, a therapy targeting Myositis.

Cabaletta Bio navigates market volatility with its Q4 2024 financial update, highlighting the company’s commitment to its mission of developing innovative T cell therapies for autoimmune diseases.